 Propafenone treatment symptomatic paroxysmal supraventricular arrhythmias randomized placebo-controlled crossover trial patients oral therapy OBJECTIVE hypothesis propafenone prevents symptomatic paroxysmal supraventricular arrhythmias DESIGN open-label dose-finding phase randomized double-blind placebo-controlled crossover phase treatment period days SETTING outpatient clinic PATIENTS Thirty-three patients paroxysmal supraventricular tachycardia paroxysmal atrial fibrillation arrhythmias electrocardiogram enrollment Twenty-three patients paroxysmal supraventricular tachycardia paroxysmal atrial fibrillation data patients efficacy analysis INTERVENTION Propafenone mg times patients mg patients mg patient placebo tablets randomized sequence MEASUREMENTS Symptomatic arrhythmia telephone transmission electrocardiogram MAIN RESULTS time first recurrence overall group patients propafenone recurrence rate arrhythmia treatment propafenone fifth recurrence rate treatment placebo CONCLUSIONS Propafenone effective symptomatic paroxysmal supraventricular arrhythmias